NCT07502716|Unknown
Compassionate Use of Ubamatamab
1 other identifier
R4018-Ubamatamab
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredMar 2026
Brief Summary
Provide Compassionate Use of Ubamatamab
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 24, 2026
Completed7 days until next milestone
First Posted
Study publicly available on registry
March 31, 2026
CompletedLast Updated
March 31, 2026
Status Verified
March 1, 2026
First QC Date
March 24, 2026
Last Update Submit
March 24, 2026
Conditions
Interventions
ubamatamabDRUG
Also known as: R4018, MUC16xCD3
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Eligibility will be determined during the application review process.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
MeSH Terms
Conditions
Sarcoma
Condition Hierarchy (Ancestors)
Neoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasms
Central Study Contacts
Requests for compassionate use must be initiated by a treating physician Physicians should contact
CONTACT
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 24, 2026
First Posted
March 31, 2026
Last Updated
March 31, 2026
Record last verified: 2026-03